Introduction Thromboembolism (TE) is common in patients with non‐small cell lung cancer (NSCLC) and is associated with worse outcomes. Recent advances in the understanding of NSCLC have led to the i…
The rule would prohibit companies from limiting their employees’ ability to work for rivals, a change that could increase competition and boost wages.
The rule would prohibit companies from limiting their employees’ ability to work for rivals, a change that could increase competition and boost wages.
Druggable oncogene-driven non–small cell lung cancer has led to innovative systemic treatment options, improving patients’ outcome. This benefit is not only achieved in the metastatic…
Aim: We assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab–platinum–pemetrexed (induction) in US community oncology…
We are currently running a fundraiser to help raise money and to ensure we have a successful season. Your donation will help us buy equipment…
Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion…
Immune checkpoint inhibitors have significantly transformed the treatment paradigm for metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving remarkable deep and durable…
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men with around 1.4 million new cases every year. In patients with localized disease,…
Immuno-oncology (IO) has made monumental gains in the past decade in the genitourinary space. In this review, we highlight advances with IO in renal cell…
Small-cell carcinomas (SCCs) of the genitourinary (GU) tract are rare malignancies with high metastatic potential. The most common primary sites are the bladder and prostate,…
